Growth Metrics

Merck (MRK) Invested Capital (2016 - 2026)

Merck has reported Invested Capital over the past 18 years, most recently at $48.3 billion for Q1 2026.

  • Quarterly Invested Capital fell 2.89% to $48.3 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $48.3 billion through Mar 2026, down 2.89% year-over-year, with the annual reading at $55.3 billion for FY2025, 12.71% up from the prior year.
  • Invested Capital was $48.3 billion for Q1 2026 at Merck, down from $55.3 billion in the prior quarter.
  • Over five years, Invested Capital peaked at $55.3 billion in Q4 2025 and troughed at $39.0 billion in Q4 2023.
  • The 5-year median for Invested Capital is $47.7 billion (2024), against an average of $47.0 billion.
  • Year-over-year, Invested Capital grew 29.05% in 2022 and then fell 18.74% in 2023.
  • A 5-year view of Invested Capital shows it stood at $48.0 billion in 2022, then fell by 18.74% to $39.0 billion in 2023, then increased by 25.67% to $49.0 billion in 2024, then grew by 12.71% to $55.3 billion in 2025, then fell by 12.54% to $48.3 billion in 2026.
  • Per Business Quant, the three most recent readings for MRK's Invested Capital are $48.3 billion (Q1 2026), $55.3 billion (Q4 2025), and $53.3 billion (Q3 2025).